Evogene Ltd. Overview
Pro stress-test →Evogene Ltd. is a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI™, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. The company underwent a strategic transformation initiated in 2025, now focused on execution and advancing its tech engine for small-molecule discovery and optimization through collaborations and internal programs.
Strategic Profile
Pro stress-test →ChemPass AI™'s competitive advantage lies in its ability to generate novel molecules while optimizing multiple critical parameters from the earliest stages of design. This powerful platform significantly improves success rates while reducing development time and costs. The company is expanding its pharma pipeline while maintaining agricultural applications as a secondary focus area.
Competitive Landscape
Pro stress-test →Evogene operates with proprietary tech-engines including MicroBoost AI, ChemPass AI, and GeneRator AI focused on microbes, small molecules, and genetic elements, used internally through subsidiaries and strategic collaborations. Primary competitors include established computational drug discovery platforms from larger pharma and dedicated AI biotech companies, with differentiation centered on multi-parameter molecular optimization.
Industry Context
Evogene Ltd. operates in AI-powered small-molecule drug discovery platforms.
Key facts
Founded: 2000s · Headquarters: Rehovot, Israel · Employees: N/A · Revenue: $3.9M (2025) · Market cap: $9.5M